Business
Intuitive Surgical designs, manufactures and markets the da Vinci robotic surgical systems and the Ion endoluminal system.
INTUITIVE SURGICAL INC: Revenue grew 20.5% to $10.065B from $8.352B. Net income grew 23.0% to $2.856B from $2.323B. Free cash flow grew 91.0% to $2.491B from $1.304B. Operating margin expanded 115 bps to 29.27%. INTUITIVE SURGICAL INC's annual comparison also shows inventory grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 20.5%OK
- Profitability — Net income grew 23.0% to $2.856B from $2.323BOK
- Cash flow — Free cash flow grew 91.0% to $2.491B from $1.304BOK
- Margins — Operating margin expanded 115 bps to 29.27%OK
- Accounting — No overriding statistical warningNote
- Insiders — 0 purchases and 52 salesWatch
Where the revenue comes from
Fiscal 2025, as INTUITIVE SURGICAL INC reports it. History and quarterly detail are in the app.
- Product$8.5B
- Instruments and accessories$6.0B
- Systems$2.5B
- Service$1.6B
Leadership changes
From INTUITIVE SURGICAL INC's own filings, the day they're filed.
- Henry L. Charlton · President · departureeff. 2026-07-01
- Brian E. Miller · Chief Digital Officer · departureeff. 2026-01-01
- Craig H. Barratt · director · appointmenteff. 2025-07-01
Latest filings
- 8-K · Company announcement2026-07-27
- 10-Q · Quarterly report2026-07-21
- 8-K · Company announcement2026-07-16
- 8-K · Company announcement2026-05-28
- 8-K · Company announcement2026-05-04
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about INTUITIVE SURGICAL INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.